Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.

Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE.

Prostate. 2012 Oct 1;72(14):1532-41. doi: 10.1002/pros.22508. Epub 2012 Apr 4. Review.

2.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
3.

Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.

Schmidt B, Anastasiadis AG, Seifert HH, Franke KH, Oya M, Ackermann R.

Anticancer Res. 2003 Sep-Oct;23(5A):3991-9.

PMID:
14666708
4.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
5.

Flow cytometric detection of prostate tumor cells using chemoaffinity labels.

Wu LY, Liu T, Grimm AL, Davis WC, Berkman CE.

Prostate. 2011 Jan 1;71(1):52-61. doi: 10.1002/pros.21221.

PMID:
20632319
6.

Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.

Ghosh A, Wang X, Klein E, Heston WD.

Cancer Res. 2005 Feb 1;65(3):727-31.

7.

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.

Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M, Ding X, Liu J, Zhu Q, Gao S.

Int J Nanomedicine. 2011;6:1747-56. doi: 10.2147/IJN.S23747. Epub 2011 Aug 19.

8.

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R.

Urology. 1996 Aug;48(2):326-34.

PMID:
8753752
9.

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL.

Int J Cancer. 2014 May 15;134(10):2284-93. doi: 10.1002/ijc.28561. Epub 2014 Jan 2.

10.

Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.

Kularatne SA, Wang K, Santhapuram HK, Low PS.

Mol Pharm. 2009 May-Jun;6(3):780-9. doi: 10.1021/mp900069d.

PMID:
19361233
11.

Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction.

Ghossein RA, Osman I, Bhattacharya S, Ferrara J, Fazzari M, Cordon-Cardo C, Scher HI.

Diagn Mol Pathol. 1999 Jun;8(2):59-65.

PMID:
10475379
12.

Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.

Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, Lin T, Huang H.

Prostate. 2013 Jun;73(8):835-41. doi: 10.1002/pros.22627. Epub 2012 Dec 19.

PMID:
23255296
13.
14.
15.

Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection.

Sabile A, Louha M, Bonte E, Poussin K, Vona G, Mejean A, Chretien Y, Bougas L, Lacour B, Capron F, Roseto A, Bréchot C, Paterlini-Bréchot P.

Am J Clin Pathol. 1999 Aug;112(2):171-8.

16.

Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.

Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA.

Electrophoresis. 2009 Sep;30(18):3289-300. doi: 10.1002/elps.200900141.

17.

High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.

Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ, Zheng BJ, Qiu SP.

Prostate. 2007 Dec 1;67(16):1791-800.

PMID:
17929272
18.

Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PT, Berkman CE.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):3931-4. doi: 10.1016/j.bmcl.2012.04.110. Epub 2012 Apr 30.

19.

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF.

J Nucl Med. 2009 Dec;50(12):2042-8. doi: 10.2967/jnumed.109.066589. Epub 2009 Nov 12.

20.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV.

Clin Cancer Res. 2003 Dec 15;9(17):6357-62.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk